MSON - Misonix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
23.27
-0.54 (-2.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close23.81
Open23.57
Bid0.00 x 800
Ask0.00 x 800
Day's Range22.77 - 24.60
52 Week Range13.04 - 27.54
Volume48,908
Avg. Volume67,269
Market Cap224.348M
Beta (3Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire15 days ago

    Misonix Announces Inclusion in the Russell 2000® and 3000 Indexes

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it has been selected to be added to the broad-market Russell 2000 and 3000® Indexes as part of the annual reconstitution of the Russell stock indexes. The Russell index changes became effective at the market close on June 28, 2019.  Misonix is already included in the Russell MicroCap Index. “We are very pleased to be added to the Russell 2000 and 3000 Indexes,” stated Stavros Vizirgianakis, President and Chief Executive Officer of Misonix.

  • GlobeNewswire26 days ago

    SEC Investigation of Misonix, Inc. Ends With No Action

    Misonix, Inc. (MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it has received a letter from the Division of Enforcement of the Securities and Exchange Commission (the “SEC”) on June 18, 2019, stating that the SEC has concluded its investigation of Misonix and that, based on the information it has as of the date of the letter, it does not intend to recommend an enforcement action by the SEC against Misonix with respect to the matters described below. As previously disclosed, with the assistance of outside counsel, Misonix conducted a voluntary investigation into the business practices of the independent Chinese entity that previously distributed Misonix’s products in China and Misonix’s knowledge of those business practices, which may have had implications under the U.S. Foreign Corrupt Practices Act, as well as into various internal controls issues identified during the investigation.

  • GlobeNewswirelast month

    Misonix Receives U.S. FDA Clearance for Nexus, its Revolutionary Integrated Ultrasonic Surgical Platform

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for Nexus, its revolutionary ultrasonic surgical platform. Misonix will commence the commercialization of the Nexus platform in the United States in July. Nexus is a next-generation integrated ultrasonic surgical platform that combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single fully integrated platform that will also serve to power future solutions.

  • GlobeNewswire2 months ago

    Misonix to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor Conference held at the Depot Renaissance Minneapolis Hotel in Minneapolis, Minnesota on Wednesday, May 29, 2019. Misonix management will be available to meet with institutional investors in one-on-one meetings throughout the day at the conference. The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com.

  • GlobeNewswire2 months ago

    Misonix Reports Fiscal 2019 Third Quarter Revenue of $9.6 Million

    FARMINGDALE, N.Y., May 08, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire2 months ago

    Misonix, Inc. Enters Into Definitive Agreement to Acquire Regenerative Medical Company Solsys Medical for Approximately $97 Million

    FARMINGDALE, N.Y., May 02, 2019 (GLOBE NEWSWIRE) --  Misonix, Inc. (MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that it has entered into a definitive agreement with Solsys Medical, LLC (“Solsys”), a privately held regenerative medical company, to acquire Solsys in an all-stock transaction valued at approximately $97 million. Under the terms of the agreement, Misonix will issue approximately 5.7 million new shares to Solsys unitholders.

  • GlobeNewswire3 months ago

    Misonix to Report Fiscal 2019 Third Quarter Financial Results and Host Conference Call and Webcast on May 8

    FARMINGDALE, N.Y., April 10, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire4 months ago

    Misonix To Present At The 9th Annual Canaccord Genuity Musculoskeletal Conference On March 12

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the 9th Annual Canaccord Genuity Musculoskeletal Conference held at the Bally's Las Vegas Hotel in Las Vegas, Nevada on Tuesday, March 12, 2019. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, is scheduled to present at 11:30 a.m. PT / 2:30 p.m. ET that day. The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com.

  • GlobeNewswire4 months ago

    Misonix Names Sharon Klugewicz Chief Operating Officer

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that Sharon Klugewicz has been appointed Chief Operating Officer. In this newly created position, Ms. Klugewicz will oversee all aspects of manufacturing, regulatory affairs, quality assurance and research & development. Ms. Klugewicz will report to Stavros Vizirgianakis, President and CEO of Misonix.

  • GlobeNewswire5 months ago

    Misonix to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the 8th Annual SVB Leerink Global Healthcare Conference held at the Lotte New York Palace Hotel in New York City on Wednesday, February 27, 2019. Misonix President and Chief Executive Officer, Stavros Vizirgianakis will be conducting a fire-side chat in the Louis Room at 2:30 p.m. ET that day. The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com.

  • GlobeNewswire5 months ago

    Misonix Fiscal 2019 Second Quarter Revenue Rises 22% to a Record $10.2 Million

    FARMINGDALE, N.Y., Feb. 06, 2019 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire6 months ago

    Misonix to Report Fiscal 2019 Second Quarter Financial Results and Host Conference Call and Webcast on February 6

    FARMINGDALE, N.Y., Jan. 22, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire8 months ago

    Analysis: Positioning to Benefit within Vertex Pharmaceuticals, MISONIX, Whiting Petroleum, Kewaunee Scientific, Arotech, and Apollo Commercial Real Estate Finance — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire8 months ago

    Misonix Fiscal 2019 First Quarter Revenue Rises 29% to Record $9.4 Million

    FARMINGDALE, N.Y., Nov. 08, 2018 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire8 months ago

    Misonix to Participate in Three Upcoming Investor Conferences

    FARMINGDALE, N.Y., Nov. 08, 2018 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.